Follow-The-Filings

Security · featured owners

WST West Pharmaceutical Svsc Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 1.9%
  • $221M
  • 2 reduce 1 exit

WST (West Pharmaceutical Svsc Inc.) is held in 3 featured 13F books as of 2026 Q2. Hillman Capital Management is the largest tracked holder by portfolio weight (1.8%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.9% (Hillman Capital Management) · not free-float ownership

  1. Hillman Capital Management reduce 1.9%
  2. Gates Foundation Trust 0.46%
  3. Ron Baron reduce 0.09%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Gates Foundation Trust 2026 Q2 0.46% Hold 444,500 $160M history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 0.09% Reduce −17.8% 164,174 $59M history
Hillman Capital Management 2026 Q2 1.9% Reduce −20.2% 7,106 $3M history
Andreas Halvorsen - Viking Global Investors exited 2026 Q2 last 2026 Q1 0.29% Exit −0.29% 416,948 $105M history

3 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 11 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K/A 1.05,9.01 Filing Doc
8-K 1.05,7.01,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 5.02,7.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 8 rows shown

Filed Form Detail Links
4 Period Sep 8, 2026 · 2 forms Filing Doc
4 Period Aug 11, 2026 Filing Doc
4 Period Jun 30, 2026 Filing Doc
4 Period May 12, 2026 Filing Doc
4 Period May 4, 2026 · 10 forms Filing Doc
4 Period Apr 27, 2026 · 2 forms Filing Doc
4 Period Mar 31, 2026 Filing Doc
4 Period Mar 1, 2026 · 7 forms Filing Doc

Updated 4 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $2.95B $2.89B $3.07B
Gross profit $1.13B $0.998B $1.1B
Gross margin * 38.3% 34.5% 35.9%
Net income $593.4M $492.7M $493.7M
Net margin * 20.1% 17.0% 16.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.94B $1.54B $1.98B
Total non-current assets * $1.89B $2.11B $2.29B
Total assets $3.83B $3.64B $4.27B
Total current liabilities $671.8M $550.4M $654.9M
Total non-current liabilities * $276.7M $410.7M $439.1M
Total equity $2.88B $2.68B $3.18B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $776.5M $653.4M $754.8M
Cash from investing -$368.7M -$378.7M -$285.9M
Cash from financing -$459.6M -$622.6M -$185.1M
Net change in cash -$40.4M -$369.3M $306.7M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders